AU774266B2 - Flt4 (VEGFR-3) as a target for tumor imaging and anti-tumor therapy - Google Patents

Info

Publication number

AU774266B2

AU774266B2 AU13121/00A AU1312100A AU774266B2 AU 774266 B2 AU774266 B2 AU 774266B2 AU 13121/00 A AU13121/00 A AU 13121/00A AU 1312100 A AU1312100 A AU 1312100A AU 774266 B2 AU774266 B2 AU 774266B2

Authority

AU

Australia

Prior art keywords

flt4

fragment

leu

polypeptide

antibody

Prior art date

1998-10-09

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Ceased

Links

• Espacenet
• Global Dossier
• Discuss

• 102000016663 Vascular Endothelial Growth Factor Receptor-3 Human genes 0.000 title claims abstract description 719
• 101150009958 FLT4 gene Proteins 0.000 title claims description 694
• 206010028980 Neoplasm Diseases 0.000 title claims description 82
• 238000003384 imaging method Methods 0.000 title claims description 20
• 238000002560 therapeutic procedure Methods 0.000 title description 8
• 108010053100 Vascular Endothelial Growth Factor Receptor-3 Proteins 0.000 title description 3
• 230000000259 anti-tumor effect Effects 0.000 title description 2
• 239000012634 fragment Substances 0.000 claims abstract description 196
• 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 184
• 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 175
• 229920001184 polypeptide Polymers 0.000 claims abstract description 152
• 210000004027 cell Anatomy 0.000 claims description 252
• 230000027455 binding Effects 0.000 claims description 170
• 241000282414 Homo sapiens Species 0.000 claims description 138
• 108010073923 Vascular Endothelial Growth Factor C Proteins 0.000 claims description 124
• 210000002889 endothelial cell Anatomy 0.000 claims description 123
• 239000000203 mixture Substances 0.000 claims description 120
• 102100038232 Vascular endothelial growth factor C Human genes 0.000 claims description 119
• 150000001875 compounds Chemical class 0.000 claims description 119
• 238000000034 method Methods 0.000 claims description 117
• 230000014509 gene expression Effects 0.000 claims description 105
• 108090000623 proteins and genes Proteins 0.000 claims description 95
• 210000004204 blood vessel Anatomy 0.000 claims description 85
• 239000000427 antigen Substances 0.000 claims description 78
• 108091007433 antigens Proteins 0.000 claims description 78
• 102000036639 antigens Human genes 0.000 claims description 78
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 76
• 108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 claims description 56
• 239000003112 inhibitor Substances 0.000 claims description 54
• 102000004169 proteins and genes Human genes 0.000 claims description 52
• 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 claims description 51
• 201000010099 disease Diseases 0.000 claims description 51
• 238000012216 screening Methods 0.000 claims description 50
• 230000002401 inhibitory effect Effects 0.000 claims description 49
• 108091008598 receptor tyrosine kinases Proteins 0.000 claims description 49
• 102000027426 receptor tyrosine kinases Human genes 0.000 claims description 49
• 239000003550 marker Substances 0.000 claims description 46
• 230000001613 neoplastic effect Effects 0.000 claims description 46
• 230000003511 endothelial effect Effects 0.000 claims description 44
• 239000008280 blood Substances 0.000 claims description 43
• 210000004369 blood Anatomy 0.000 claims description 41
• 239000003814 drug Substances 0.000 claims description 39
• 201000011510 cancer Diseases 0.000 claims description 38
• 230000001926 lymphatic effect Effects 0.000 claims description 35
• 230000002792 vascular Effects 0.000 claims description 34
• BJHCYTJNPVGSBZ-YXSASFKJSA-N 1-[4-[6-amino-5-[(Z)-methoxyiminomethyl]pyrimidin-4-yl]oxy-2-chlorophenyl]-3-ethylurea Chemical compound CCNC(=O)Nc1ccc(Oc2ncnc(N)c2\C=N/OC)cc1Cl BJHCYTJNPVGSBZ-YXSASFKJSA-N 0.000 claims description 33
• 230000035755 proliferation Effects 0.000 claims description 32
• 210000003556 vascular endothelial cell Anatomy 0.000 claims description 32
• 239000003446 ligand Substances 0.000 claims description 31
• 238000011282 treatment Methods 0.000 claims description 30
• 230000001404 mediated effect Effects 0.000 claims description 29
• 238000002360 preparation method Methods 0.000 claims description 27
• 208000026310 Breast neoplasm Diseases 0.000 claims description 25
• 208000035475 disorder Diseases 0.000 claims description 25
• 108010073919 Vascular Endothelial Growth Factor D Proteins 0.000 claims description 23
• 206010006187 Breast cancer Diseases 0.000 claims description 22
• 238000004519 manufacturing process Methods 0.000 claims description 20
• 241000251539 Vertebrata <Metazoa> Species 0.000 claims description 19
• 238000001514 detection method Methods 0.000 claims description 19
• 108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 17
• 102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 17
• 229940034982 antineoplastic agent Drugs 0.000 claims description 13
• 239000002246 antineoplastic agent Substances 0.000 claims description 13
• 101000742596 Homo sapiens Vascular endothelial growth factor C Proteins 0.000 claims description 12
• 239000003795 chemical substances by application Substances 0.000 claims description 12
• 238000005406 washing Methods 0.000 claims description 12
• 201000009030 Carcinoma Diseases 0.000 claims description 11
• 239000002671 adjuvant Substances 0.000 claims description 11
• 239000002243 precursor Substances 0.000 claims description 9
• 241000124008 Mammalia Species 0.000 claims description 8
• 230000002596 correlated effect Effects 0.000 claims description 8
• 238000009826 distribution Methods 0.000 claims description 8
• 101600105505 Mus musculus Vascular endothelial growth factor C (isoform 1) Proteins 0.000 claims description 7
• 201000008275 breast carcinoma Diseases 0.000 claims description 7
• 230000009826 neoplastic cell growth Effects 0.000 claims description 7
• 102000016549 Vascular Endothelial Growth Factor Receptor-2 Human genes 0.000 claims description 6
• 102100033178 Vascular endothelial growth factor receptor 1 Human genes 0.000 claims description 6
• 230000003042 antagnostic effect Effects 0.000 claims description 6
• 206010025323 Lymphomas Diseases 0.000 claims description 5
• 239000003085 diluting agent Substances 0.000 claims description 5
• 108010053096 Vascular Endothelial Growth Factor Receptor-1 Proteins 0.000 claims description 4
• 230000008859 change Effects 0.000 claims description 4
• 230000036210 malignancy Effects 0.000 claims description 4
• -1 compound compound Chemical class 0.000 claims description 3
• 239000003937 drug carrier Substances 0.000 claims description 3
• 201000001441 melanoma Diseases 0.000 claims description 3
• 206010039491 Sarcoma Diseases 0.000 claims description 2
• 238000011160 research Methods 0.000 claims description 2
• 206010041823 squamous cell carcinoma Diseases 0.000 claims description 2
• 102000009519 Vascular Endothelial Growth Factor D Human genes 0.000 claims 7
• WZZBNLYBHUDSHF-DHLKQENFSA-N 1-[(3s,4s)-4-[8-(2-chloro-4-pyrimidin-2-yloxyphenyl)-7-fluoro-2-methylimidazo[4,5-c]quinolin-1-yl]-3-fluoropiperidin-1-yl]-2-hydroxyethanone Chemical compound CC1=NC2=CN=C3C=C(F)C(C=4C(=CC(OC=5N=CC=CN=5)=CC=4)Cl)=CC3=C2N1[C@H]1CCN(C(=O)CO)C[C@@H]1F WZZBNLYBHUDSHF-DHLKQENFSA-N 0.000 claims 1
• 102000040430 polynucleotide Human genes 0.000 abstract description 3
• 108091033319 polynucleotide Proteins 0.000 abstract description 3
• 239000002157 polynucleotide Substances 0.000 abstract description 3
• 210000001519 tissue Anatomy 0.000 description 95
• 108020004999 messenger RNA Proteins 0.000 description 67
• 239000002299 complementary DNA Substances 0.000 description 57
• 235000018102 proteins Nutrition 0.000 description 49
• 108020003175 receptors Proteins 0.000 description 46
• 102000005962 receptors Human genes 0.000 description 45
• 239000000523 sample Substances 0.000 description 43
• 108091032973 (ribonucleotides)n+m Proteins 0.000 description 36
• 230000006870 function Effects 0.000 description 32
• 238000010186 staining Methods 0.000 description 32
• 241000699666 Mus <mouse, genus> Species 0.000 description 31
• 235000001014 amino acid Nutrition 0.000 description 29
• 238000004458 analytical method Methods 0.000 description 29
• 238000009396 hybridization Methods 0.000 description 29
• 210000001365 lymphatic vessel Anatomy 0.000 description 29
• 150000001413 amino acids Chemical class 0.000 description 28
• 239000013598 vector Substances 0.000 description 28
• 108020004414 DNA Proteins 0.000 description 26
• 229940024606 amino acid Drugs 0.000 description 26
• 108091008605 VEGF receptors Proteins 0.000 description 25
• 102000009524 Vascular Endothelial Growth Factor A Human genes 0.000 description 25
• 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 25
• 239000002773 nucleotide Substances 0.000 description 25
• 125000003729 nucleotide group Chemical group 0.000 description 25
• 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 24
• 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 description 24
• 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 24
• LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 24
• 239000002953 phosphate buffered saline Substances 0.000 description 24
• 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 22
• 125000003275 alpha amino acid group Chemical group 0.000 description 22
• 238000011161 development Methods 0.000 description 22
• 230000018109 developmental process Effects 0.000 description 22
• 230000000694 effects Effects 0.000 description 22
• 210000002257 embryonic structure Anatomy 0.000 description 22
• 239000000047 product Substances 0.000 description 21
• 210000004072 lung Anatomy 0.000 description 20
• 108091028043 Nucleic acid sequence Proteins 0.000 description 18
• 239000003636 conditioned culture medium Substances 0.000 description 18
• 230000000875 corresponding effect Effects 0.000 description 18
• 239000013604 expression vector Substances 0.000 description 17
• 210000004408 hybridoma Anatomy 0.000 description 17
• 238000003556 assay Methods 0.000 description 16
• 238000010367 cloning Methods 0.000 description 16
• 238000010790 dilution Methods 0.000 description 16
• 239000012895 dilution Substances 0.000 description 16
• 239000002609 medium Substances 0.000 description 16
• 239000000243 solution Substances 0.000 description 16
• 108091003079 Bovine Serum Albumin Proteins 0.000 description 15
• 108091026890 Coding region Proteins 0.000 description 15
• 241000699670 Mus sp. Species 0.000 description 15
• 102100038234 Vascular endothelial growth factor D Human genes 0.000 description 15
• 210000001165 lymph node Anatomy 0.000 description 15
• 208000037396 Intraductal Noninfiltrating Carcinoma Diseases 0.000 description 14
• 230000004069 differentiation Effects 0.000 description 14
• 210000003754 fetus Anatomy 0.000 description 14
• 210000002966 serum Anatomy 0.000 description 14
• 230000001225 therapeutic effect Effects 0.000 description 14
• 241000283973 Oryctolagus cuniculus Species 0.000 description 13
• 230000033115 angiogenesis Effects 0.000 description 13
• 239000003102 growth factor Substances 0.000 description 13
• 238000007901 in situ hybridization Methods 0.000 description 13
• 238000003752 polymerase chain reaction Methods 0.000 description 13
• CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 12
• 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 12
• OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 11
• 108020004511 Recombinant DNA Proteins 0.000 description 11
• 210000000481 breast Anatomy 0.000 description 11
• 210000000349 chromosome Anatomy 0.000 description 11
• 208000032839 leukemia Diseases 0.000 description 11
• 102000039446 nucleic acids Human genes 0.000 description 11
• 108020004707 nucleic acids Proteins 0.000 description 11
• 150000007523 nucleic acids Chemical class 0.000 description 11
• 241000894007 species Species 0.000 description 11
• 210000004881 tumor cell Anatomy 0.000 description 11
• OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 11
• 108020005544 Antisense RNA Proteins 0.000 description 10
• 108010001463 Collagen Type XVIII Proteins 0.000 description 10
• 102000047200 Collagen Type XVIII Human genes 0.000 description 10
• 108091034117 Oligonucleotide Proteins 0.000 description 10
• 229920002684 Sepharose Polymers 0.000 description 10
• DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 10
• JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 10
• 125000000539 amino acid group Chemical group 0.000 description 10
• 230000004071 biological effect Effects 0.000 description 10
• 210000003038 endothelium Anatomy 0.000 description 10
• 238000011534 incubation Methods 0.000 description 10
• 239000000126 substance Substances 0.000 description 10
• 238000006467 substitution reaction Methods 0.000 description 10
• 108020004635 Complementary DNA Proteins 0.000 description 9
• WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 9
• 108700020796 Oncogene Proteins 0.000 description 9
• 230000035578 autophosphorylation Effects 0.000 description 9
• 210000004556 brain Anatomy 0.000 description 9
• 238000004113 cell culture Methods 0.000 description 9
• 238000002474 experimental method Methods 0.000 description 9
• 230000026731 phosphorylation Effects 0.000 description 9
• 238000006366 phosphorylation reaction Methods 0.000 description 9
• 239000013612 plasmid Substances 0.000 description 9
• 235000019333 sodium laurylsulphate Nutrition 0.000 description 9
• 210000000264 venule Anatomy 0.000 description 9
• DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 8
• 238000000636 Northern blotting Methods 0.000 description 8
• 108091034057 RNA (poly(A)) Proteins 0.000 description 8
• 238000013459 approach Methods 0.000 description 8
• 239000003184 complementary RNA Substances 0.000 description 8
• 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 8
• 230000001086 cytosolic effect Effects 0.000 description 8
• 230000004927 fusion Effects 0.000 description 8
• 108020001507 fusion proteins Proteins 0.000 description 8
• 102000037865 fusion proteins Human genes 0.000 description 8
• 239000000499 gel Substances 0.000 description 8
• 238000000338 in vitro Methods 0.000 description 8
• 210000003734 kidney Anatomy 0.000 description 8
• 210000004185 liver Anatomy 0.000 description 8
• 210000004324 lymphatic system Anatomy 0.000 description 8
• 239000000463 material Substances 0.000 description 8
• 102000013415 peroxidase activity proteins Human genes 0.000 description 8
• 108040007629 peroxidase activity proteins Proteins 0.000 description 8
• 210000002826 placenta Anatomy 0.000 description 8
• 239000006228 supernatant Substances 0.000 description 8
• 210000005166 vasculature Anatomy 0.000 description 8
• 239000003981 vehicle Substances 0.000 description 8
• 210000003462 vein Anatomy 0.000 description 8
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
• 238000001262 western blot Methods 0.000 description 8
• WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 7
• HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 7
• 238000001042 affinity chromatography Methods 0.000 description 7
• 239000005557 antagonist Substances 0.000 description 7
• 230000000692 anti-sense effect Effects 0.000 description 7
• 210000002469 basement membrane Anatomy 0.000 description 7
• 230000015572 biosynthetic process Effects 0.000 description 7
• 238000012217 deletion Methods 0.000 description 7
• 230000037430 deletion Effects 0.000 description 7
• 238000005516 engineering process Methods 0.000 description 7
• 239000012894 fetal calf serum Substances 0.000 description 7
• 230000001605 fetal effect Effects 0.000 description 7
• 230000012010 growth Effects 0.000 description 7
• 210000002216 heart Anatomy 0.000 description 7
• 229960002897 heparin Drugs 0.000 description 7
• 229920000669 heparin Polymers 0.000 description 7
• 230000001965 increasing effect Effects 0.000 description 7
• 210000001161 mammalian embryo Anatomy 0.000 description 7
• 230000004044 response Effects 0.000 description 7
• 230000004936 stimulating effect Effects 0.000 description 7
• 230000000638 stimulation Effects 0.000 description 7
• ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 6
• 108060003951 Immunoglobulin Proteins 0.000 description 6
• 241001465754 Metazoa Species 0.000 description 6
• OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
• 101100372771 Mus musculus Flt4 gene Proteins 0.000 description 6
• 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 6
• 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 6
• 108010076504 Protein Sorting Signals Proteins 0.000 description 6
• YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
• 210000000648 angioblast Anatomy 0.000 description 6
• 210000001736 capillary Anatomy 0.000 description 6
• 230000000295 complement effect Effects 0.000 description 6
• 238000012137 double-staining Methods 0.000 description 6
• 208000028715 ductal breast carcinoma in situ Diseases 0.000 description 6
• 230000003053 immunization Effects 0.000 description 6
• 238000002649 immunization Methods 0.000 description 6
• 102000018358 immunoglobulin Human genes 0.000 description 6
• 238000012744 immunostaining Methods 0.000 description 6
• 210000005073 lymphatic endothelial cell Anatomy 0.000 description 6
• 210000001077 lymphatic endothelium Anatomy 0.000 description 6
• 239000012528 membrane Substances 0.000 description 6
• 230000004048 modification Effects 0.000 description 6
• 238000012986 modification Methods 0.000 description 6
• 238000012545 processing Methods 0.000 description 6
• 241000282412 Homo Species 0.000 description 5
• 206010025219 Lymphangioma Diseases 0.000 description 5
• 241000699660 Mus musculus Species 0.000 description 5
• VXOKDLACQICQFA-UHFFFAOYSA-N N-Desethylamiodarone Chemical compound CCCCC=1OC2=CC=CC=C2C=1C(=O)C1=CC(I)=C(OCCNCC)C(I)=C1 VXOKDLACQICQFA-UHFFFAOYSA-N 0.000 description 5
• 239000000020 Nitrocellulose Substances 0.000 description 5
• 108091000080 Phosphotransferase Proteins 0.000 description 5
• 241000700159 Rattus Species 0.000 description 5
• 241000282898 Sus scrofa Species 0.000 description 5
• SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 5
• 230000004075 alteration Effects 0.000 description 5
• 239000003242 anti bacterial agent Substances 0.000 description 5
• 229940088710 antibiotic agent Drugs 0.000 description 5
• 239000012472 biological sample Substances 0.000 description 5
• 229940098773 bovine serum albumin Drugs 0.000 description 5
• 239000000872 buffer Substances 0.000 description 5
• 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 5
• 230000010261 cell growth Effects 0.000 description 5
• 239000013592 cell lysate Substances 0.000 description 5
• 238000012512 characterization method Methods 0.000 description 5
• 239000003153 chemical reaction reagent Substances 0.000 description 5
• 238000003776 cleavage reaction Methods 0.000 description 5
• 238000003745 diagnosis Methods 0.000 description 5
• 229940079593 drug Drugs 0.000 description 5
• 210000003527 eukaryotic cell Anatomy 0.000 description 5
• 230000002209 hydrophobic effect Effects 0.000 description 5
• 239000012133 immunoprecipitate Substances 0.000 description 5
• 238000001114 immunoprecipitation Methods 0.000 description 5
• 230000001394 metastastic effect Effects 0.000 description 5
• 206010061289 metastatic neoplasm Diseases 0.000 description 5
• 244000005700 microbiome Species 0.000 description 5
• 229920001220 nitrocellulos Polymers 0.000 description 5
• 230000001575 pathological effect Effects 0.000 description 5
• 102000020233 phosphotransferase Human genes 0.000 description 5
• XOJVVFBFDXDTEG-UHFFFAOYSA-N pristane Chemical compound CC(C)CCCC(C)CCCC(C)CCCC(C)C XOJVVFBFDXDTEG-UHFFFAOYSA-N 0.000 description 5
• 238000000746 purification Methods 0.000 description 5
• 230000033458 reproduction Effects 0.000 description 5
• 229930002330 retinoic acid Natural products 0.000 description 5
• 230000007017 scission Effects 0.000 description 5
• 230000011664 signaling Effects 0.000 description 5
• 210000000952 spleen Anatomy 0.000 description 5
• 238000003786 synthesis reaction Methods 0.000 description 5
• 229960001727 tretinoin Drugs 0.000 description 5
• 210000001325 yolk sac Anatomy 0.000 description 5
• YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
• 102000040650 (ribonucleotides)n+m Human genes 0.000 description 4
• FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 4
• 108020004705 Codon Proteins 0.000 description 4
• 208000031637 Erythroblastic Acute Leukemia Diseases 0.000 description 4
• 208000036566 Erythroleukaemia Diseases 0.000 description 4
• 108700024394 Exon Proteins 0.000 description 4
• 239000004471 Glycine Substances 0.000 description 4
• 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 4
• FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 4
• 206010027476 Metastases Diseases 0.000 description 4
• 101100372766 Mus musculus Kdr gene Proteins 0.000 description 4
• 229930193140 Neomycin Natural products 0.000 description 4
• 108700026244 Open Reading Frames Proteins 0.000 description 4
• 241000286209 Phasianidae Species 0.000 description 4
• 239000007983 Tris buffer Substances 0.000 description 4
• XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 4
• 239000002253 acid Substances 0.000 description 4
• 208000021841 acute erythroid leukemia Diseases 0.000 description 4
• 238000007792 addition Methods 0.000 description 4
• 230000002491 angiogenic effect Effects 0.000 description 4
• 210000001367 artery Anatomy 0.000 description 4
• 239000012131 assay buffer Substances 0.000 description 4
• 239000012298 atmosphere Substances 0.000 description 4
• 230000001580 bacterial effect Effects 0.000 description 4
• 230000033228 biological regulation Effects 0.000 description 4
• 238000010804 cDNA synthesis Methods 0.000 description 4
• 210000002808 connective tissue Anatomy 0.000 description 4
• 235000018417 cysteine Nutrition 0.000 description 4
• 210000005260 human cell Anatomy 0.000 description 4
• 238000003018 immunoassay Methods 0.000 description 4
• 238000003125 immunofluorescent labeling Methods 0.000 description 4
• 230000002163 immunogen Effects 0.000 description 4
• 208000015181 infectious disease Diseases 0.000 description 4
• 239000007924 injection Substances 0.000 description 4
• 238000002347 injection Methods 0.000 description 4
• 230000003834 intracellular effect Effects 0.000 description 4
• 208000030776 invasive breast carcinoma Diseases 0.000 description 4
• 238000002955 isolation Methods 0.000 description 4
• 238000002372 labelling Methods 0.000 description 4
• 238000011068 loading method Methods 0.000 description 4
• 210000004698 lymphocyte Anatomy 0.000 description 4
• 210000003563 lymphoid tissue Anatomy 0.000 description 4
• 239000006166 lysate Substances 0.000 description 4
• 210000004379 membrane Anatomy 0.000 description 4
• 229960004452 methionine Drugs 0.000 description 4
• 229960004927 neomycin Drugs 0.000 description 4
• 210000000056 organ Anatomy 0.000 description 4
• 230000008569 process Effects 0.000 description 4
• 230000001105 regulatory effect Effects 0.000 description 4
• 238000012552 review Methods 0.000 description 4
• 208000001608 teratocarcinoma Diseases 0.000 description 4
• 238000012360 testing method Methods 0.000 description 4
• 210000002978 thoracic duct Anatomy 0.000 description 4
• 238000001890 transfection Methods 0.000 description 4
• 230000032258 transport Effects 0.000 description 4
• 230000004614 tumor growth Effects 0.000 description 4
• 210000003606 umbilical vein Anatomy 0.000 description 4
• MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 3
• QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 3
• 102000002260 Alkaline Phosphatase Human genes 0.000 description 3
• 108020004774 Alkaline Phosphatase Proteins 0.000 description 3
• 206010003445 Ascites Diseases 0.000 description 3
• DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 3
• 241000894006 Bacteria Species 0.000 description 3
• BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 3
• IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
• KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
• 102000009465 Growth Factor Receptors Human genes 0.000 description 3
• 108010009202 Growth Factor Receptors Proteins 0.000 description 3
• 101000851007 Homo sapiens Vascular endothelial growth factor receptor 2 Proteins 0.000 description 3
• QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 3
• DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 3
• AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 3
• 241001529936 Murinae Species 0.000 description 3
• 241001197446 Mus cypriacus Species 0.000 description 3
• 101100335081 Mus musculus Flt3 gene Proteins 0.000 description 3
• 206010029113 Neovascularisation Diseases 0.000 description 3
• 108020004711 Nucleic Acid Probes Proteins 0.000 description 3
• 108010029485 Protein Isoforms Proteins 0.000 description 3
• 102000001708 Protein Isoforms Human genes 0.000 description 3
• 108010014608 Proto-Oncogene Proteins c-kit Proteins 0.000 description 3
• 102000016971 Proto-Oncogene Proteins c-kit Human genes 0.000 description 3
• 239000012083 RIPA buffer Substances 0.000 description 3
• 108020004518 RNA Probes Proteins 0.000 description 3
• 239000003391 RNA probe Substances 0.000 description 3
• 208000034541 Rare lymphatic malformation Diseases 0.000 description 3
• 201000000582 Retinoblastoma Diseases 0.000 description 3
• 102000006382 Ribonucleases Human genes 0.000 description 3
• 108010083644 Ribonucleases Proteins 0.000 description 3
• MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 3
• AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 3
• 239000004473 Threonine Substances 0.000 description 3
• 235000004279 alanine Nutrition 0.000 description 3
• 210000001643 allantois Anatomy 0.000 description 3
• 239000002870 angiogenesis inducing agent Substances 0.000 description 3
• 210000000709 aorta Anatomy 0.000 description 3
• 210000002403 aortic endothelial cell Anatomy 0.000 description 3
• 235000009582 asparagine Nutrition 0.000 description 3
• 229960001230 asparagine Drugs 0.000 description 3
• 238000000211 autoradiogram Methods 0.000 description 3
• 210000003719 b-lymphocyte Anatomy 0.000 description 3
• 201000003149 breast fibroadenoma Diseases 0.000 description 3
• 229910002091 carbon monoxide Inorganic materials 0.000 description 3
• 238000005119 centrifugation Methods 0.000 description 3
• 238000006243 chemical reaction Methods 0.000 description 3
• 230000021615 conjugation Effects 0.000 description 3
• 239000002872 contrast media Substances 0.000 description 3
• 239000012228 culture supernatant Substances 0.000 description 3
• ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical class BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 3
• 229940127089 cytotoxic agent Drugs 0.000 description 3
• 239000002254 cytotoxic agent Substances 0.000 description 3
• 231100000599 cytotoxic agent Toxicity 0.000 description 3
• 238000001378 electrochemiluminescence detection Methods 0.000 description 3
• 239000000839 emulsion Substances 0.000 description 3
• 210000003989 endothelium vascular Anatomy 0.000 description 3
• 230000002255 enzymatic effect Effects 0.000 description 3
• 239000012091 fetal bovine serum Substances 0.000 description 3
• 239000012530 fluid Substances 0.000 description 3
• 239000001963 growth medium Substances 0.000 description 3
• 210000003128 head Anatomy 0.000 description 3
• 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 3
• 230000001900 immune effect Effects 0.000 description 3
• 230000002055 immunohistochemical effect Effects 0.000 description 3
• 238000011532 immunohistochemical staining Methods 0.000 description 3
• 230000001976 improved effect Effects 0.000 description 3
• 238000011065 in-situ storage Methods 0.000 description 3
• 230000003993 interaction Effects 0.000 description 3
• 208000024312 invasive carcinoma Diseases 0.000 description 3
• 238000001638 lipofection Methods 0.000 description 3
• 238000012423 maintenance Methods 0.000 description 3
• 229930182817 methionine Natural products 0.000 description 3
• 238000013508 migration Methods 0.000 description 3
• 229940126619 mouse monoclonal antibody Drugs 0.000 description 3
• 239000013642 negative control Substances 0.000 description 3
• 239000002853 nucleic acid probe Substances 0.000 description 3
• 238000011275 oncology therapy Methods 0.000 description 3
• 210000002741 palatine tonsil Anatomy 0.000 description 3
• 239000012188 paraffin wax Substances 0.000 description 3
• 210000003668 pericyte Anatomy 0.000 description 3
• 238000002823 phage display Methods 0.000 description 3
• 230000008488 polyadenylation Effects 0.000 description 3
• 239000013641 positive control Substances 0.000 description 3
• 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
• 239000013615 primer Substances 0.000 description 3
• 230000019491 signal transduction Effects 0.000 description 3
• 210000002027 skeletal muscle Anatomy 0.000 description 3
• 210000000329 smooth muscle myocyte Anatomy 0.000 description 3
• 238000010561 standard procedure Methods 0.000 description 3
• 239000000758 substrate Substances 0.000 description 3
• 238000011830 transgenic mouse model Methods 0.000 description 3
• LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 3
• IHIXIJGXTJIKRB-UHFFFAOYSA-N trisodium vanadate Chemical compound [Na+].[Na+].[Na+].[O-][V]([O-])([O-])=O IHIXIJGXTJIKRB-UHFFFAOYSA-N 0.000 description 3
• 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 3
• 241000701447 unidentified baculovirus Species 0.000 description 3
• 230000004862 vasculogenesis Effects 0.000 description 3
• 108010047303 von Willebrand Factor Proteins 0.000 description 3
• 102100036537 von Willebrand factor Human genes 0.000 description 3
• WYTZZXDRDKSJID-UHFFFAOYSA-N (3-aminopropyl)triethoxysilane Chemical compound CCO[Si](OCC)(OCC)CCCN WYTZZXDRDKSJID-UHFFFAOYSA-N 0.000 description 2
• RSMRWWHFJMENJH-LQDDAWAPSA-M 2,3-bis[[(z)-octadec-9-enoyl]oxy]propyl-trimethylazanium;methyl sulfate Chemical compound COS([O-])(=O)=O.CCCCCCCC\C=C/CCCCCCCC(=O)OCC(C[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC RSMRWWHFJMENJH-LQDDAWAPSA-M 0.000 description 2
• BHNQPLPANNDEGL-UHFFFAOYSA-N 2-(4-octylphenoxy)ethanol Chemical compound CCCCCCCCC1=CC=C(OCCO)C=C1 BHNQPLPANNDEGL-UHFFFAOYSA-N 0.000 description 2
• 102000007469 Actins Human genes 0.000 description 2
• 108010085238 Actins Proteins 0.000 description 2
• 108010039627 Aprotinin Proteins 0.000 description 2
• 239000004475 Arginine Substances 0.000 description 2
• IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
• 241000972773 Aulopiformes Species 0.000 description 2
• 241000271566 Aves Species 0.000 description 2
• 102000000844 Cell Surface Receptors Human genes 0.000 description 2
• 108010001857 Cell Surface Receptors Proteins 0.000 description 2
• 102000004127 Cytokines Human genes 0.000 description 2
• 108090000695 Cytokines Proteins 0.000 description 2
• 239000003155 DNA primer Substances 0.000 description 2
• 229920002307 Dextran Polymers 0.000 description 2
• AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
• 238000002965 ELISA Methods 0.000 description 2
• 102000004190 Enzymes Human genes 0.000 description 2
• 108090000790 Enzymes Proteins 0.000 description 2
• 241000588724 Escherichia coli Species 0.000 description 2
• 241000701959 Escherichia virus Lambda Species 0.000 description 2
• 229910052693 Europium Inorganic materials 0.000 description 2
• 102000018233 Fibroblast Growth Factor Human genes 0.000 description 2
• 108050007372 Fibroblast Growth Factor Proteins 0.000 description 2
• 229920001917 Ficoll Polymers 0.000 description 2
• WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
• 102000005720 Glutathione transferase Human genes 0.000 description 2
• 108010070675 Glutathione transferase Proteins 0.000 description 2
• 102000003886 Glycoproteins Human genes 0.000 description 2
• 108090000288 Glycoproteins Proteins 0.000 description 2
• 108090000100 Hepatocyte Growth Factor Proteins 0.000 description 2
• 102100021866 Hepatocyte growth factor Human genes 0.000 description 2
• 101000916644 Homo sapiens Macrophage colony-stimulating factor 1 receptor Proteins 0.000 description 2
• 101000851018 Homo sapiens Vascular endothelial growth factor receptor 1 Proteins 0.000 description 2
• MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
• 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 2
• 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 2
• 206010061218 Inflammation Diseases 0.000 description 2
• 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 2
• 102100037852 Insulin-like growth factor I Human genes 0.000 description 2
• 108091092195 Intron Proteins 0.000 description 2
• 208000007766 Kaposi sarcoma Diseases 0.000 description 2
• 101150088608 Kdr gene Proteins 0.000 description 2
• CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
• WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
• ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
• AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 2
• ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
• KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 2
• FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 2
• COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
• ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
• KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
• 239000004472 Lysine Substances 0.000 description 2
• 108010058398 Macrophage Colony-Stimulating Factor Receptor Proteins 0.000 description 2
• 102100028198 Macrophage colony-stimulating factor 1 receptor Human genes 0.000 description 2
• 241000713869 Moloney murine leukemia virus Species 0.000 description 2
• 241001467552 Mycobacterium bovis BCG Species 0.000 description 2
• CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 2
• 108091008606 PDGF receptors Proteins 0.000 description 2
• 108020002230 Pancreatic Ribonuclease Proteins 0.000 description 2
• 102000005891 Pancreatic ribonuclease Human genes 0.000 description 2
• 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 2
• 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 2
• 102100035194 Placenta growth factor Human genes 0.000 description 2
• 208000007452 Plasmacytoma Diseases 0.000 description 2
• 239000004365 Protease Substances 0.000 description 2
• 102000009572 RNA Polymerase II Human genes 0.000 description 2
• 108010009460 RNA Polymerase II Proteins 0.000 description 2
• 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
• 108091081021 Sense strand Proteins 0.000 description 2
• CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
• 108010006830 TIE receptors Proteins 0.000 description 2
• 102000005450 TIE receptors Human genes 0.000 description 2
• 241000700605 Viruses Species 0.000 description 2
• 208000008383 Wilms tumor Diseases 0.000 description 2
• 230000002159 abnormal effect Effects 0.000 description 2
• 150000007513 acids Chemical class 0.000 description 2
• 238000005904 alkaline hydrolysis reaction Methods 0.000 description 2
• 238000010171 animal model Methods 0.000 description 2
• 230000000118 anti-neoplastic effect Effects 0.000 description 2
• 230000000890 antigenic effect Effects 0.000 description 2
• 229960004405 aprotinin Drugs 0.000 description 2
• ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
• 235000003704 aspartic acid Nutrition 0.000 description 2
• 229960000190 bacillus calmette–guérin vaccine Drugs 0.000 description 2
• 230000008901 benefit Effects 0.000 description 2
• OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 2
• 229960002685 biotin Drugs 0.000 description 2
• 235000020958 biotin Nutrition 0.000 description 2
• 239000011616 biotin Substances 0.000 description 2
• 239000002981 blocking agent Substances 0.000 description 2
• 230000000903 blocking effect Effects 0.000 description 2
• 210000000601 blood cell Anatomy 0.000 description 2
• 239000004202 carbamide Substances 0.000 description 2
• 230000003197 catalytic effect Effects 0.000 description 2
• 239000006143 cell culture medium Substances 0.000 description 2
• 210000000170 cell membrane Anatomy 0.000 description 2
• 230000001413 cellular effect Effects 0.000 description 2
• 238000004587 chromatography analysis Methods 0.000 description 2
• 230000002759 chromosomal effect Effects 0.000 description 2
• 230000014107 chromosome localization Effects 0.000 description 2
• 238000010276 construction Methods 0.000 description 2
• XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
• 208000003688 cystic lymphangioma Diseases 0.000 description 2
• 230000003247 decreasing effect Effects 0.000 description 2
• 229960003964 deoxycholic acid Drugs 0.000 description 2
• KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 2
• 230000029087 digestion Effects 0.000 description 2
• 239000013024 dilution buffer Substances 0.000 description 2
• 239000000539 dimer Substances 0.000 description 2
• 238000006471 dimerization reaction Methods 0.000 description 2
• 210000001174 endocardium Anatomy 0.000 description 2
• 230000002124 endocrine Effects 0.000 description 2
• 108091007231 endothelial receptors Proteins 0.000 description 2
• 229940088598 enzyme Drugs 0.000 description 2
• 210000003743 erythrocyte Anatomy 0.000 description 2
• ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 2
• 229960005542 ethidium bromide Drugs 0.000 description 2
• 210000003191 femoral vein Anatomy 0.000 description 2
• 239000011521 glass Substances 0.000 description 2
• 235000013922 glutamic acid Nutrition 0.000 description 2
• 239000004220 glutamic acid Substances 0.000 description 2
• ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
• RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
• 230000013595 glycosylation Effects 0.000 description 2
• 238000006206 glycosylation reaction Methods 0.000 description 2
• 238000012333 histopathological diagnosis Methods 0.000 description 2
• 210000003917 human chromosome Anatomy 0.000 description 2
• 210000004754 hybrid cell Anatomy 0.000 description 2
• 239000012216 imaging agent Substances 0.000 description 2
• 230000028993 immune response Effects 0.000 description 2
• 230000016784 immunoglobulin production Effects 0.000 description 2
• 229940072221 immunoglobulins Drugs 0.000 description 2
• 201000004933 in situ carcinoma Diseases 0.000 description 2
• 230000006698 induction Effects 0.000 description 2
• 230000001939 inductive effect Effects 0.000 description 2
• 230000004054 inflammatory process Effects 0.000 description 2
• 230000005764 inhibitory process Effects 0.000 description 2
• ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 2
• 239000003999 initiator Substances 0.000 description 2
• 238000003780 insertion Methods 0.000 description 2
• 230000037431 insertion Effects 0.000 description 2
• NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
• 239000007928 intraperitoneal injection Substances 0.000 description 2
• 230000002601 intratumoral effect Effects 0.000 description 2
• 206010073096 invasive lobular breast carcinoma Diseases 0.000 description 2
• AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 2
• 229960000310 isoleucine Drugs 0.000 description 2
• 230000002147 killing effect Effects 0.000 description 2
• 230000003902 lesion Effects 0.000 description 2
• 238000013507 mapping Methods 0.000 description 2
• 210000003716 mesoderm Anatomy 0.000 description 2
• 238000001466 metabolic labeling Methods 0.000 description 2
• 230000009401 metastasis Effects 0.000 description 2
• 229960000485 methotrexate Drugs 0.000 description 2
• 238000005497 microtitration Methods 0.000 description 2
• 238000012544 monitoring process Methods 0.000 description 2
• 210000001616 monocyte Anatomy 0.000 description 2
• 210000000496 pancreas Anatomy 0.000 description 2
• 230000036961 partial effect Effects 0.000 description 2
• 230000007170 pathology Effects 0.000 description 2
• COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 2
• YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
• 229920002401 polyacrylamide Polymers 0.000 description 2
• 229920002981 polyvinylidene fluoride Polymers 0.000 description 2
• 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
• 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
• 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
• 230000003389 potentiating effect Effects 0.000 description 2
• 229940002612 prodrug Drugs 0.000 description 2
• 239000000651 prodrug Substances 0.000 description 2
• 230000002062 proliferating effect Effects 0.000 description 2
• 230000002797 proteolythic effect Effects 0.000 description 2
• 230000002285 radioactive effect Effects 0.000 description 2
• 238000003259 recombinant expression Methods 0.000 description 2
• 230000002441 reversible effect Effects 0.000 description 2
• 235000019515 salmon Nutrition 0.000 description 2
• 238000007423 screening assay Methods 0.000 description 2
• 238000012163 sequencing technique Methods 0.000 description 2
• 210000000813 small intestine Anatomy 0.000 description 2
• 150000003384 small molecules Chemical class 0.000 description 2
• 239000011780 sodium chloride Substances 0.000 description 2
• 239000001509 sodium citrate Substances 0.000 description 2
• NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 2
• 230000009870 specific binding Effects 0.000 description 2
• 230000003393 splenic effect Effects 0.000 description 2
• 239000013589 supplement Substances 0.000 description 2
• 210000001550 testis Anatomy 0.000 description 2
• 229940124597 therapeutic agent Drugs 0.000 description 2
• 229940104230 thymidine Drugs 0.000 description 2
• 210000001541 thymus gland Anatomy 0.000 description 2
• 238000013518 transcription Methods 0.000 description 2
• 230000035897 transcription Effects 0.000 description 2
• 230000002103 transcriptional effect Effects 0.000 description 2
• 230000009466 transformation Effects 0.000 description 2
• 230000014621 translational initiation Effects 0.000 description 2
• 230000005945 translocation Effects 0.000 description 2
• 239000008096 xylene Substances 0.000 description 2
• DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
• WZUVPPKBWHMQCE-XJKSGUPXSA-N (+)-haematoxylin Chemical compound C12=CC(O)=C(O)C=C2C[C@]2(O)[C@H]1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-XJKSGUPXSA-N 0.000 description 1
• ASWBNKHCZGQVJV-UHFFFAOYSA-N (3-hexadecanoyloxy-2-hydroxypropyl) 2-(trimethylazaniumyl)ethyl phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(O)COP([O-])(=O)OCC[N+](C)(C)C ASWBNKHCZGQVJV-UHFFFAOYSA-N 0.000 description 1
• OVSKIKFHRZPJSS-UHFFFAOYSA-N 2,4-D Chemical compound OC(=O)COC1=CC=C(Cl)C=C1Cl OVSKIKFHRZPJSS-UHFFFAOYSA-N 0.000 description 1
• UFBJCMHMOXMLKC-UHFFFAOYSA-N 2,4-dinitrophenol Chemical compound OC1=CC=C([N+]([O-])=O)C=C1[N+]([O-])=O UFBJCMHMOXMLKC-UHFFFAOYSA-N 0.000 description 1
• BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
• HSTOKWSFWGCZMH-UHFFFAOYSA-N 3,3'-diaminobenzidine Chemical compound C1=C(N)C(N)=CC=C1C1=CC=C(N)C(N)=C1 HSTOKWSFWGCZMH-UHFFFAOYSA-N 0.000 description 1
• LHYQAEFVHIZFLR-UHFFFAOYSA-L 4-(4-diazonio-3-methoxyphenyl)-2-methoxybenzenediazonium;dichloride Chemical compound [Cl-].[Cl-].C1=C([N+]#N)C(OC)=CC(C=2C=C(OC)C([N+]#N)=CC=2)=C1 LHYQAEFVHIZFLR-UHFFFAOYSA-L 0.000 description 1
• CXNVOWPRHWWCQR-UHFFFAOYSA-N 4-Chloro-ortho-toluidine Chemical compound CC1=CC(Cl)=CC=C1N CXNVOWPRHWWCQR-UHFFFAOYSA-N 0.000 description 1
• TVZGACDUOSZQKY-LBPRGKRZSA-N 4-aminofolic acid Chemical compound C1=NC2=NC(N)=NC(N)=C2N=C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 TVZGACDUOSZQKY-LBPRGKRZSA-N 0.000 description 1
• OXEUETBFKVCRNP-UHFFFAOYSA-N 9-ethyl-3-carbazolamine Chemical compound NC1=CC=C2N(CC)C3=CC=CC=C3C2=C1 OXEUETBFKVCRNP-UHFFFAOYSA-N 0.000 description 1
• 208000036762 Acute promyelocytic leukaemia Diseases 0.000 description 1
• 206010001233 Adenoma benign Diseases 0.000 description 1
• HJCMDXDYPOUFDY-WHFBIAKZSA-N Ala-Gln Chemical compound C[C@H](N)C(=O)N[C@H](C(O)=O)CCC(N)=O HJCMDXDYPOUFDY-WHFBIAKZSA-N 0.000 description 1
• 102400000068 Angiostatin Human genes 0.000 description 1
• 108010079709 Angiostatins Proteins 0.000 description 1
• 108020000948 Antisense Oligonucleotides Proteins 0.000 description 1
• 206010003210 Arteriosclerosis Diseases 0.000 description 1
• 101710192393 Attachment protein G3P Proteins 0.000 description 1
• 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 1
• 102100039705 Beta-2 adrenergic receptor Human genes 0.000 description 1
• 241000283690 Bos taurus Species 0.000 description 1
• 201000011057 Breast sarcoma Diseases 0.000 description 1
• 238000011749 CBA mouse Methods 0.000 description 1
• 241000283707 Capra Species 0.000 description 1
• 208000009458 Carcinoma in Situ Diseases 0.000 description 1
• 241000282693 Cercopithecidae Species 0.000 description 1
• 102000019034 Chemokines Human genes 0.000 description 1
• 108010012236 Chemokines Proteins 0.000 description 1
• 208000006332 Choriocarcinoma Diseases 0.000 description 1
• 108010074466 Chromosomal Puffs Proteins 0.000 description 1
• 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 1
• 108090000317 Chymotrypsin Proteins 0.000 description 1
• KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
• 101100007328 Cocos nucifera COS-1 gene Proteins 0.000 description 1
• 102000008186 Collagen Human genes 0.000 description 1
• 108010035532 Collagen Proteins 0.000 description 1
• 108010003384 Colony-Stimulating Factor Receptors Proteins 0.000 description 1
• 102000004626 Colony-Stimulating Factor Receptors Human genes 0.000 description 1
• 108010047041 Complementarity Determining Regions Proteins 0.000 description 1
• 108091035707 Consensus sequence Proteins 0.000 description 1
• 241000557626 Corvus corax Species 0.000 description 1
• 241000186216 Corynebacterium Species 0.000 description 1
• 241000288030 Coturnix coturnix Species 0.000 description 1
• 102000053602 DNA Human genes 0.000 description 1
• 238000007900 DNA-DNA hybridization Methods 0.000 description 1
• 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
• 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
• 208000006402 Ductal Carcinoma Diseases 0.000 description 1
• 238000012286 ELISA Assay Methods 0.000 description 1
• 239000006145 Eagle's minimal essential medium Substances 0.000 description 1
• 241000196324 Embryophyta Species 0.000 description 1
• 102000012085 Endoglin Human genes 0.000 description 1
• 108010036395 Endoglin Proteins 0.000 description 1
• 108010042407 Endonucleases Proteins 0.000 description 1
• 102000004533 Endonucleases Human genes 0.000 description 1
• 108010067770 Endopeptidase K Proteins 0.000 description 1
• 108010059378 Endopeptidases Proteins 0.000 description 1
• 102000005593 Endopeptidases Human genes 0.000 description 1
• 102400001047 Endostatin Human genes 0.000 description 1
• 108010079505 Endostatins Proteins 0.000 description 1
• 239000004593 Epoxy Substances 0.000 description 1
• 208000032027 Essential Thrombocythemia Diseases 0.000 description 1
• 241000206602 Eukaryota Species 0.000 description 1
• 102000018389 Exopeptidases Human genes 0.000 description 1
• 108010091443 Exopeptidases Proteins 0.000 description 1
• 108050001049 Extracellular proteins Proteins 0.000 description 1
• 206010015866 Extravasation Diseases 0.000 description 1
• 102000008857 Ferritin Human genes 0.000 description 1
• 108050000784 Ferritin Proteins 0.000 description 1
• 238000008416 Ferritin Methods 0.000 description 1
• 208000007659 Fibroadenoma Diseases 0.000 description 1
• 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 1
• 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 1
• 102100027844 Fibroblast growth factor receptor 4 Human genes 0.000 description 1
• 101710182387 Fibroblast growth factor receptor 4 Proteins 0.000 description 1
• 241000724791 Filamentous phage Species 0.000 description 1
• 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 1
• 101150112014 Gapdh gene Proteins 0.000 description 1
• 108010010803 Gelatin Proteins 0.000 description 1
• 108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
• SXGAGTVDWKQYCX-BQBZGAKWSA-N Glu-Met Chemical compound CSCC[C@@H](C(O)=O)NC(=O)[C@@H](N)CCC(O)=O SXGAGTVDWKQYCX-BQBZGAKWSA-N 0.000 description 1
• 108010051815 Glutamyl endopeptidase Proteins 0.000 description 1
• 108010024636 Glutathione Proteins 0.000 description 1
• 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
• 241000238631 Hexapoda Species 0.000 description 1
• 101000959437 Homo sapiens Beta-2 adrenergic receptor Proteins 0.000 description 1
• 101001001487 Homo sapiens Phosphatidylinositol-glycan biosynthesis class F protein Proteins 0.000 description 1
• 101000595923 Homo sapiens Placenta growth factor Proteins 0.000 description 1
• 101000932478 Homo sapiens Receptor-type tyrosine-protein kinase FLT3 Proteins 0.000 description 1
• 101000808011 Homo sapiens Vascular endothelial growth factor A Proteins 0.000 description 1
• 101000742599 Homo sapiens Vascular endothelial growth factor D Proteins 0.000 description 1
• 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
• 206010021143 Hypoxia Diseases 0.000 description 1
• 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 description 1
• 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 description 1
• 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
• 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
• 102000016844 Immunoglobulin-like domains Human genes 0.000 description 1
• 108050006430 Immunoglobulin-like domains Proteins 0.000 description 1
• 108090001061 Insulin Proteins 0.000 description 1
• 102000004877 Insulin Human genes 0.000 description 1
• 102100032999 Integrin beta-3 Human genes 0.000 description 1
• 108010020950 Integrin beta3 Proteins 0.000 description 1
• 241000274177 Juniperus sabina Species 0.000 description 1
• ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
• HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
• QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
• KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
• 206010024305 Leukaemia monocytic Diseases 0.000 description 1
• 208000000265 Lobular Carcinoma Diseases 0.000 description 1
• 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
• 208000004138 Lymphangiomyoma Diseases 0.000 description 1
• 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
• 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
• 101000851005 Mus musculus Vascular endothelial growth factor receptor 2 Proteins 0.000 description 1
• 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 1
• 208000014767 Myeloproliferative disease Diseases 0.000 description 1
• 238000011785 NMRI mouse Methods 0.000 description 1
• 229910002651 NO3 Inorganic materials 0.000 description 1
• NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
• 108020005187 Oligonucleotide Probes Proteins 0.000 description 1
• 239000012124 Opti-MEM Substances 0.000 description 1
• 101710160107 Outer membrane protein A Proteins 0.000 description 1
• 108090000526 Papain Proteins 0.000 description 1
• 229930040373 Paraformaldehyde Natural products 0.000 description 1
• 241000237988 Patellidae Species 0.000 description 1
• 102000057297 Pepsin A Human genes 0.000 description 1
• 108090000284 Pepsin A Proteins 0.000 description 1
• 108091005804 Peptidases Proteins 0.000 description 1
• 102000035195 Peptidases Human genes 0.000 description 1
• 102000007079 Peptide Fragments Human genes 0.000 description 1
• 108010033276 Peptide Fragments Proteins 0.000 description 1
• 241000009328 Perro Species 0.000 description 1
• 229940122907 Phosphatase inhibitor Drugs 0.000 description 1
• 108010089430 Phosphoproteins Proteins 0.000 description 1
• 102000007982 Phosphoproteins Human genes 0.000 description 1
• 108010082093 Placenta Growth Factor Proteins 0.000 description 1
• 231100000742 Plant toxin Toxicity 0.000 description 1
• 206010035226 Plasma cell myeloma Diseases 0.000 description 1
• 102000013566 Plasminogen Human genes 0.000 description 1
• 108010051456 Plasminogen Proteins 0.000 description 1
• 108010022233 Plasminogen Activator Inhibitor 1 Proteins 0.000 description 1
• 108010001014 Plasminogen Activators Proteins 0.000 description 1
• 102000001938 Plasminogen Activators Human genes 0.000 description 1
• 102100039418 Plasminogen activator inhibitor 1 Human genes 0.000 description 1
• 102000011653 Platelet-Derived Growth Factor Receptors Human genes 0.000 description 1
• 102100037596 Platelet-derived growth factor subunit A Human genes 0.000 description 1
• 102000002727 Protein Tyrosine Phosphatase Human genes 0.000 description 1
• 108020005067 RNA Splice Sites Proteins 0.000 description 1
• 239000013614 RNA sample Substances 0.000 description 1
• 241000700157 Rattus norvegicus Species 0.000 description 1
• 101100008569 Rattus norvegicus Cst4 gene Proteins 0.000 description 1
• 102100020718 Receptor-type tyrosine-protein kinase FLT3 Human genes 0.000 description 1
• 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
• 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
• 208000009527 Refractory anemia Diseases 0.000 description 1
• 208000033501 Refractory anemia with excess blasts Diseases 0.000 description 1
• 206010072684 Refractory cytopenia with unilineage dysplasia Diseases 0.000 description 1
• 108010039491 Ricin Proteins 0.000 description 1
• 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
• 102000014400 SH2 domains Human genes 0.000 description 1
• 108050003452 SH2 domains Proteins 0.000 description 1
• 108060006706 SRC Proteins 0.000 description 1
• 102000001332 SRC Human genes 0.000 description 1
• 108010084592 Saporins Proteins 0.000 description 1
• 238000012300 Sequence Analysis Methods 0.000 description 1
• 206010072170 Skin wound Diseases 0.000 description 1
• 208000037065 Subacute sclerosing leukoencephalitis Diseases 0.000 description 1
• 206010042297 Subacute sclerosing panencephalitis Diseases 0.000 description 1
• 208000000389 T-cell leukemia Diseases 0.000 description 1
• 239000004098 Tetracycline Substances 0.000 description 1
• 102000006601 Thymidine Kinase Human genes 0.000 description 1
• 108020004440 Thymidine kinase Proteins 0.000 description 1
• 108020004566 Transfer RNA Proteins 0.000 description 1
• 108010009583 Transforming Growth Factors Proteins 0.000 description 1
• 102000009618 Transforming Growth Factors Human genes 0.000 description 1
• 108700019146 Transgenes Proteins 0.000 description 1
• 108090000631 Trypsin Proteins 0.000 description 1
• 102000004142 Trypsin Human genes 0.000 description 1
• QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
• 101150117115 V gene Proteins 0.000 description 1
• GIAZPLMMQOERPN-YUMQZZPRSA-N Val-Pro Chemical compound CC(C)[C@H](N)C(=O)N1CCC[C@H]1C(O)=O GIAZPLMMQOERPN-YUMQZZPRSA-N 0.000 description 1
• KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
• 229940122803 Vinca alkaloid Drugs 0.000 description 1
• 206010000210 abortion Diseases 0.000 description 1
• 231100000176 abortion Toxicity 0.000 description 1
• 238000002835 absorbance Methods 0.000 description 1
• 238000010521 absorption reaction Methods 0.000 description 1
• 230000021736 acetylation Effects 0.000 description 1
• 238000006640 acetylation reaction Methods 0.000 description 1
• 230000002378 acidificating effect Effects 0.000 description 1
• 208000017733 acquired polycythemia vera Diseases 0.000 description 1
• 230000004913 activation Effects 0.000 description 1
• 239000012190 activator Substances 0.000 description 1
• 239000013543 active substance Substances 0.000 description 1
• 230000001154 acute effect Effects 0.000 description 1
• 208000009956 adenocarcinoma Diseases 0.000 description 1
• 230000001919 adrenal effect Effects 0.000 description 1
• 229940009456 adriamycin Drugs 0.000 description 1
• 238000001261 affinity purification Methods 0.000 description 1
• 239000011543 agarose gel Substances 0.000 description 1
• 230000004520 agglutination Effects 0.000 description 1
• 238000013019 agitation Methods 0.000 description 1
• 239000000556 agonist Substances 0.000 description 1
• 230000001270 agonistic effect Effects 0.000 description 1
• 125000001931 aliphatic group Chemical group 0.000 description 1
• 229940100198 alkylating agent Drugs 0.000 description 1
• 239000002168 alkylating agent Substances 0.000 description 1
• WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
• 229910021502 aluminium hydroxide Inorganic materials 0.000 description 1
• 150000001408 amides Chemical group 0.000 description 1
• 229960003896 aminopterin Drugs 0.000 description 1
• 229960000723 ampicillin Drugs 0.000 description 1
• AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
• 230000003321 amplification Effects 0.000 description 1
• 239000004037 angiogenesis inhibitor Substances 0.000 description 1
• 210000004102 animal cell Anatomy 0.000 description 1
• 230000000340 anti-metabolite Effects 0.000 description 1
• 230000005875 antibody response Effects 0.000 description 1
• 238000011319 anticancer therapy Methods 0.000 description 1
• 229940100197 antimetabolite Drugs 0.000 description 1
• 239000002256 antimetabolite Substances 0.000 description 1
• 239000003080 antimitotic agent Substances 0.000 description 1
• 239000000074 antisense oligonucleotide Substances 0.000 description 1
• 238000012230 antisense oligonucleotides Methods 0.000 description 1
• 208000011775 arteriosclerosis disease Diseases 0.000 description 1
• 125000003118 aryl group Chemical group 0.000 description 1
• FZCSTZYAHCUGEM-UHFFFAOYSA-N aspergillomarasmine B Natural products OC(=O)CNC(C(O)=O)CNC(C(O)=O)CC(O)=O FZCSTZYAHCUGEM-UHFFFAOYSA-N 0.000 description 1
• 229910052789 astatine Inorganic materials 0.000 description 1
• 230000003190 augmentative effect Effects 0.000 description 1
• 239000000688 bacterial toxin Substances 0.000 description 1
• 239000011324 bead Substances 0.000 description 1
• 230000006399 behavior Effects 0.000 description 1
• 230000000975 bioactive effect Effects 0.000 description 1
• 230000008827 biological function Effects 0.000 description 1
• 229910052797 bismuth Inorganic materials 0.000 description 1
• 230000023555 blood coagulation Effects 0.000 description 1
• 230000037396 body weight Effects 0.000 description 1
• 210000001185 bone marrow Anatomy 0.000 description 1
• 210000002798 bone marrow cell Anatomy 0.000 description 1
• 201000003714 breast lobular carcinoma Diseases 0.000 description 1
• 201000009613 breast lymphoma Diseases 0.000 description 1
• 201000000488 breast squamous cell carcinoma Diseases 0.000 description 1
• 210000004899 c-terminal region Anatomy 0.000 description 1
• 239000001506 calcium phosphate Substances 0.000 description 1
• 229960001714 calcium phosphate Drugs 0.000 description 1
• 229910000389 calcium phosphate Inorganic materials 0.000 description 1
• 235000011010 calcium phosphates Nutrition 0.000 description 1
• 239000012830 cancer therapeutic Substances 0.000 description 1
• 150000001720 carbohydrates Chemical class 0.000 description 1
• 210000001715 carotid artery Anatomy 0.000 description 1
• 239000000969 carrier Substances 0.000 description 1
• 230000024245 cell differentiation Effects 0.000 description 1
• 230000003915 cell function Effects 0.000 description 1
• 230000012292 cell migration Effects 0.000 description 1
• 230000009134 cell regulation Effects 0.000 description 1
• 210000001638 cerebellum Anatomy 0.000 description 1
• 239000013522 chelant Substances 0.000 description 1
• 239000013043 chemical agent Substances 0.000 description 1
• 238000007385 chemical modification Methods 0.000 description 1
• 239000003638 chemical reducing agent Substances 0.000 description 1
• 238000002038 chemiluminescence detection Methods 0.000 description 1
• 230000035605 chemotaxis Effects 0.000 description 1
• 210000000038 chest Anatomy 0.000 description 1
• 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
• 229960004630 chlorambucil Drugs 0.000 description 1
• JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 1
• 210000003711 chorioallantoic membrane Anatomy 0.000 description 1
• 210000002987 choroid plexus Anatomy 0.000 description 1
• 210000003799 chromosomal puff Anatomy 0.000 description 1
• 230000001684 chronic effect Effects 0.000 description 1
• 229960002376 chymotrypsin Drugs 0.000 description 1
• 238000011260 co-administration Methods 0.000 description 1
• 229920001436 collagen Polymers 0.000 description 1
• 201000010897 colon adenocarcinoma Diseases 0.000 description 1
• 230000001276 controlling effect Effects 0.000 description 1
• 230000001054 cortical effect Effects 0.000 description 1
• 230000008878 coupling Effects 0.000 description 1
• 238000010168 coupling process Methods 0.000 description 1
• 238000005859 coupling reaction Methods 0.000 description 1
• 150000001944 cysteine derivatives Chemical class 0.000 description 1
• 208000014014 cystic hygroma Diseases 0.000 description 1
• 230000007423 decrease Effects 0.000 description 1
• 238000012751 densitometric scanning analysis Methods 0.000 description 1
• 230000001419 dependent effect Effects 0.000 description 1
• 230000001627 detrimental effect Effects 0.000 description 1
• 239000000032 diagnostic agent Substances 0.000 description 1
• 229940039227 diagnostic agent Drugs 0.000 description 1
• 238000002059 diagnostic imaging Methods 0.000 description 1
• ZFTFAPZRGNKQPU-UHFFFAOYSA-N dicarbonic acid Chemical compound OC(=O)OC(O)=O ZFTFAPZRGNKQPU-UHFFFAOYSA-N 0.000 description 1
• 230000003292 diminished effect Effects 0.000 description 1
• 231100000676 disease causative agent Toxicity 0.000 description 1
• 230000005059 dormancy Effects 0.000 description 1
• 239000002552 dosage form Substances 0.000 description 1
• 238000003182 dose-response assay Methods 0.000 description 1
• 231100000673 dose–response relationship Toxicity 0.000 description 1
• 230000003828 downregulation Effects 0.000 description 1
• 230000009977 dual effect Effects 0.000 description 1
• 238000001493 electron microscopy Methods 0.000 description 1
• 230000008030 elimination Effects 0.000 description 1
• 238000003379 elimination reaction Methods 0.000 description 1
• 239000003480 eluent Substances 0.000 description 1
• 238000010828 elution Methods 0.000 description 1
• 230000013020 embryo development Effects 0.000 description 1
• 210000001900 endoderm Anatomy 0.000 description 1
• 229940066758 endopeptidases Drugs 0.000 description 1
• 210000002472 endoplasmic reticulum Anatomy 0.000 description 1
• 210000002919 epithelial cell Anatomy 0.000 description 1
• 210000000981 epithelium Anatomy 0.000 description 1
• 230000000925 erythroid effect Effects 0.000 description 1
• OGPBJKLSAFTDLK-UHFFFAOYSA-N europium atom Chemical compound [Eu] OGPBJKLSAFTDLK-UHFFFAOYSA-N 0.000 description 1
• 230000001747 exhibiting effect Effects 0.000 description 1
• 230000036251 extravasation Effects 0.000 description 1
• GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
• 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
• 210000003953 foreskin Anatomy 0.000 description 1
• 230000022244 formylation Effects 0.000 description 1
• 238000006170 formylation reaction Methods 0.000 description 1
• NGGMYCMLYOUNGM-CSDLUJIJSA-N fumagillin Chemical class C([C@H]([C@H]([C@@H]1[C@]2(C)[C@H](O2)CC=C(C)C)OC)OC(=O)\C=C\C=C\C=C\C=C\C(O)=O)C[C@@]21CO2 NGGMYCMLYOUNGM-CSDLUJIJSA-N 0.000 description 1
• 230000002538 fungal effect Effects 0.000 description 1
• 239000008273 gelatin Substances 0.000 description 1
• 229920000159 gelatin Polymers 0.000 description 1
• 235000019322 gelatine Nutrition 0.000 description 1
• 235000011852 gelatine desserts Nutrition 0.000 description 1
• 230000002068 genetic effect Effects 0.000 description 1
• 238000010353 genetic engineering Methods 0.000 description 1
• 210000004602 germ cell Anatomy 0.000 description 1
• 210000001654 germ layer Anatomy 0.000 description 1
• 229960003180 glutathione Drugs 0.000 description 1
• 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
• PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
• 229910052737 gold Inorganic materials 0.000 description 1
• 239000010931 gold Substances 0.000 description 1
• 239000000122 growth hormone Substances 0.000 description 1
• 230000003394 haemopoietic effect Effects 0.000 description 1
• 230000035876 healing Effects 0.000 description 1
• 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
• 108060003552 hemocyanin Proteins 0.000 description 1
• HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
• 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 1
• 230000003054 hormonal effect Effects 0.000 description 1
• 229940088597 hormone Drugs 0.000 description 1
• 102000058223 human VEGFA Human genes 0.000 description 1
• 102000058238 human VEGFC Human genes 0.000 description 1
• 235000003642 hunger Nutrition 0.000 description 1
• 229910052739 hydrogen Inorganic materials 0.000 description 1
• 230000007954 hypoxia Effects 0.000 description 1
• 208000026278 immune system disease Diseases 0.000 description 1
• 229940127121 immunoconjugate Drugs 0.000 description 1
• 238000001727 in vivo Methods 0.000 description 1
• 238000011503 in vivo imaging Methods 0.000 description 1
• 238000010348 incorporation Methods 0.000 description 1
• 230000002458 infectious effect Effects 0.000 description 1
• 230000002757 inflammatory effect Effects 0.000 description 1
• 208000014674 injury Diseases 0.000 description 1
• 229910052500 inorganic mineral Inorganic materials 0.000 description 1
• 229940125396 insulin Drugs 0.000 description 1
• 239000000138 intercalating agent Substances 0.000 description 1
• 230000009545 invasion Effects 0.000 description 1
• 206010073095 invasive ductal breast carcinoma Diseases 0.000 description 1
• 201000010985 invasive ductal carcinoma Diseases 0.000 description 1
• 238000005342 ion exchange Methods 0.000 description 1
• 208000022013 kidney Wilms tumor Diseases 0.000 description 1
• 239000007788 liquid Substances 0.000 description 1
• 230000004807 localization Effects 0.000 description 1
• 230000007774 longterm Effects 0.000 description 1
• 201000005296 lung carcinoma Diseases 0.000 description 1
• 206010025382 macrocytosis Diseases 0.000 description 1
• 210000002540 macrophage Anatomy 0.000 description 1
• 230000005291 magnetic effect Effects 0.000 description 1
• 201000010893 malignant breast melanoma Diseases 0.000 description 1
• 230000003211 malignant effect Effects 0.000 description 1
• 230000013011 mating Effects 0.000 description 1
• 239000011159 matrix material Substances 0.000 description 1
• 230000035800 maturation Effects 0.000 description 1
• 230000007246 mechanism Effects 0.000 description 1
• 210000002418 meninge Anatomy 0.000 description 1
• 230000004060 metabolic process Effects 0.000 description 1
• 208000037819 metastatic cancer Diseases 0.000 description 1
• 208000011575 metastatic malignant neoplasm Diseases 0.000 description 1
• CVRPVRHBAOPDIG-UHFFFAOYSA-N methyl 2-methylprop-2-enoate;2-(2-methylprop-2-enoyloxy)ethyl 1,3-dioxo-2-benzofuran-5-carboxylate Chemical compound COC(=O)C(C)=C.CC(=C)C(=O)OCCOC(=O)C1=CC=C2C(=O)OC(=O)C2=C1 CVRPVRHBAOPDIG-UHFFFAOYSA-N 0.000 description 1
• 230000000813 microbial effect Effects 0.000 description 1
• 210000004088 microvessel Anatomy 0.000 description 1
• 230000005012 migration Effects 0.000 description 1
• 235000013336 milk Nutrition 0.000 description 1
• 239000008267 milk Substances 0.000 description 1
• 210000004080 milk Anatomy 0.000 description 1
• 230000003278 mimic effect Effects 0.000 description 1
• 239000011707 mineral Substances 0.000 description 1
• 230000002297 mitogenic effect Effects 0.000 description 1
• 230000008747 mitogenic response Effects 0.000 description 1
• 238000010369 molecular cloning Methods 0.000 description 1
• 239000003068 molecular probe Substances 0.000 description 1
• 201000006894 monocytic leukemia Diseases 0.000 description 1
• 238000010172 mouse model Methods 0.000 description 1
• 210000003205 muscle Anatomy 0.000 description 1
• 230000003387 muscular Effects 0.000 description 1
• 239000002636 mycotoxin Substances 0.000 description 1
• 208000016586 myelodysplastic syndrome with excess blasts Diseases 0.000 description 1
• 206010028537 myelofibrosis Diseases 0.000 description 1
• 208000025113 myeloid leukemia Diseases 0.000 description 1
• 201000000050 myeloid neoplasm Diseases 0.000 description 1
• 210000005170 neoplastic cell Anatomy 0.000 description 1
• 201000008026 nephroblastoma Diseases 0.000 description 1
• 210000001020 neural plate Anatomy 0.000 description 1
• 230000004031 neuronal differentiation Effects 0.000 description 1
• 230000003472 neutralizing effect Effects 0.000 description 1
• 229910052757 nitrogen Inorganic materials 0.000 description 1
• 102000042567 non-coding RNA Human genes 0.000 description 1
• 238000010606 normalization Methods 0.000 description 1
• 238000003199 nucleic acid amplification method Methods 0.000 description 1
• 239000002751 oligonucleotide probe Substances 0.000 description 1
• 230000002018 overexpression Effects 0.000 description 1
• 230000003647 oxidation Effects 0.000 description 1
• 238000007254 oxidation reaction Methods 0.000 description 1
• 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
• 210000004923 pancreatic tissue Anatomy 0.000 description 1
• 206010033675 panniculitis Diseases 0.000 description 1
• 229940055729 papain Drugs 0.000 description 1
• 235000019834 papain Nutrition 0.000 description 1
• 230000003076 paracrine Effects 0.000 description 1
• 229920002866 paraformaldehyde Polymers 0.000 description 1
• 230000005298 paramagnetic effect Effects 0.000 description 1
• 239000002245 particle Substances 0.000 description 1
• 229940111202 pepsin Drugs 0.000 description 1
• 238000010647 peptide synthesis reaction Methods 0.000 description 1
• 230000002093 peripheral effect Effects 0.000 description 1
• 230000035699 permeability Effects 0.000 description 1
• 150000002978 peroxides Chemical class 0.000 description 1
• 230000002085 persistent effect Effects 0.000 description 1
• PHEDXBVPIONUQT-RGYGYFBISA-N phorbol 13-acetate 12-myristate Chemical compound C([C@]1(O)C(=O)C(C)=C[C@H]1[C@@]1(O)[C@H](C)[C@H]2OC(=O)CCCCCCCCCCCCC)C(CO)=C[C@H]1[C@H]1[C@]2(OC(C)=O)C1(C)C PHEDXBVPIONUQT-RGYGYFBISA-N 0.000 description 1
• 150000003905 phosphatidylinositols Chemical class 0.000 description 1
• 230000035479 physiological effects, processes and functions Effects 0.000 description 1
• 239000003123 plant toxin Substances 0.000 description 1
• 239000013600 plasmid vector Substances 0.000 description 1
• 229940127126 plasminogen activator Drugs 0.000 description 1
• 108010017843 platelet-derived growth factor A Proteins 0.000 description 1
• 229920001983 poloxamer Polymers 0.000 description 1
• 229920000447 polyanionic polymer Polymers 0.000 description 1
• 208000037244 polycythemia vera Diseases 0.000 description 1
• 229920005862 polyol Polymers 0.000 description 1
• 150000003077 polyols Chemical class 0.000 description 1
• 230000004481 post-translational protein modification Effects 0.000 description 1
• 230000001323 posttranslational effect Effects 0.000 description 1
• 239000000843 powder Substances 0.000 description 1
• 239000002244 precipitate Substances 0.000 description 1
• 238000001556 precipitation Methods 0.000 description 1
• 208000003476 primary myelofibrosis Diseases 0.000 description 1
• 230000037452 priming Effects 0.000 description 1
• 238000004393 prognosis Methods 0.000 description 1
• 150000003180 prostaglandins Chemical class 0.000 description 1
• 201000005825 prostate adenocarcinoma Diseases 0.000 description 1
• 230000009822 protein phosphorylation Effects 0.000 description 1
• 108020000494 protein-tyrosine phosphatase Proteins 0.000 description 1
• 230000017854 proteolysis Effects 0.000 description 1
• 238000003156 radioimmunoprecipitation Methods 0.000 description 1
• 230000033300 receptor internalization Effects 0.000 description 1
• 238000011084 recovery Methods 0.000 description 1
• 230000002829 reductive effect Effects 0.000 description 1
• 230000026267 regulation of growth Effects 0.000 description 1
• 210000005084 renal tissue Anatomy 0.000 description 1
• 230000008521 reorganization Effects 0.000 description 1
• 230000008439 repair process Effects 0.000 description 1
• 230000010076 replication Effects 0.000 description 1
• 230000003362 replicative effect Effects 0.000 description 1
• 238000002271 resection Methods 0.000 description 1
• 108091008146 restriction endonucleases Proteins 0.000 description 1
• 230000000717 retained effect Effects 0.000 description 1
• 238000010839 reverse transcription Methods 0.000 description 1
• 238000003757 reverse transcription PCR Methods 0.000 description 1
• 201000009410 rhabdomyosarcoma Diseases 0.000 description 1
• PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
• 230000022932 ruffle assembly Effects 0.000 description 1
• 210000003079 salivary gland Anatomy 0.000 description 1
• 230000003248 secreting effect Effects 0.000 description 1
• 238000002741 site-directed mutagenesis Methods 0.000 description 1
• 210000002460 smooth muscle Anatomy 0.000 description 1
• 210000004894 snout Anatomy 0.000 description 1
• 239000011734 sodium Substances 0.000 description 1
• 229910052708 sodium Inorganic materials 0.000 description 1
• 229910000029 sodium carbonate Inorganic materials 0.000 description 1
• 208000013274 squamous cell breast carcinoma Diseases 0.000 description 1
• 230000010473 stable expression Effects 0.000 description 1
• 230000037351 starvation Effects 0.000 description 1
• 210000000130 stem cell Anatomy 0.000 description 1
• 210000004304 subcutaneous tissue Anatomy 0.000 description 1
• FIAFUQMPZJWCLV-UHFFFAOYSA-N suramin Chemical class OS(=O)(=O)C1=CC(S(O)(=O)=O)=C2C(NC(=O)C3=CC=C(C(=C3)NC(=O)C=3C=C(NC(=O)NC=4C=C(C=CC=4)C(=O)NC=4C(=CC=C(C=4)C(=O)NC=4C5=C(C=C(C=C5C(=CC=4)S(O)(=O)=O)S(O)(=O)=O)S(O)(=O)=O)C)C=CC=3)C)=CC=C(S(O)(=O)=O)C2=C1 FIAFUQMPZJWCLV-UHFFFAOYSA-N 0.000 description 1
• 229960005314 suramin Drugs 0.000 description 1
• 238000007910 systemic administration Methods 0.000 description 1
• 238000002626 targeted therapy Methods 0.000 description 1
• 229960002180 tetracycline Drugs 0.000 description 1
• 229930101283 tetracycline Natural products 0.000 description 1
• 235000019364 tetracycline Nutrition 0.000 description 1
• 150000003522 tetracyclines Chemical class 0.000 description 1
• GCTNBVHDRFKLLK-UHFFFAOYSA-N thujane Natural products CC1CCC2(C(C)C)C1C2 GCTNBVHDRFKLLK-UHFFFAOYSA-N 0.000 description 1
• 230000001988 toxicity Effects 0.000 description 1
• 231100000419 toxicity Toxicity 0.000 description 1
• 239000003053 toxin Substances 0.000 description 1
• 231100000765 toxin Toxicity 0.000 description 1
• 108700012359 toxins Proteins 0.000 description 1
• 238000003151 transfection method Methods 0.000 description 1
• 230000001131 transforming effect Effects 0.000 description 1
• 238000013519 translation Methods 0.000 description 1
• 102000027257 transmembrane receptors Human genes 0.000 description 1
• 108091008578 transmembrane receptors Proteins 0.000 description 1
• 230000008733 trauma Effects 0.000 description 1
• 238000011269 treatment regimen Methods 0.000 description 1
• QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
• 208000029387 trophoblastic neoplasm Diseases 0.000 description 1
• 239000012588 trypsin Substances 0.000 description 1
• 230000005747 tumor angiogenesis Effects 0.000 description 1
• 239000000717 tumor promoter Substances 0.000 description 1
• DZGWFCGJZKJUFP-UHFFFAOYSA-N tyramine Chemical compound NCCC1=CC=C(O)C=C1 DZGWFCGJZKJUFP-UHFFFAOYSA-N 0.000 description 1
• 229940121358 tyrosine kinase inhibitor Drugs 0.000 description 1
• 239000005483 tyrosine kinase inhibitor Substances 0.000 description 1
• 108091005990 tyrosine-phosphorylated proteins Proteins 0.000 description 1
• 230000003827 upregulation Effects 0.000 description 1
• VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
• 239000004474 valine Substances 0.000 description 1
• LSGOVYNHVSXFFJ-UHFFFAOYSA-N vanadate(3-) Chemical compound [O-][V]([O-])([O-])=O LSGOVYNHVSXFFJ-UHFFFAOYSA-N 0.000 description 1
• 230000006459 vascular development Effects 0.000 description 1
• 230000000982 vasogenic effect Effects 0.000 description 1
• 210000001631 vena cava inferior Anatomy 0.000 description 1
• 230000002861 ventricular Effects 0.000 description 1
• 229960001134 von willebrand factor Drugs 0.000 description 1
• 239000001993 wax Substances 0.000 description 1
• 230000029663 wound healing Effects 0.000 description 1
• 229910052727 yttrium Inorganic materials 0.000 description 1